Equities analysts forecast that Merit Medical Systems, Inc. (NASDAQ:MMSI) will report earnings of $0.50 per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Merit Medical Systems’ earnings. The highest EPS estimate is $0.51 and the lowest is $0.49. Merit Medical Systems reported earnings per share of $0.43 during the same quarter last year, which indicates a positive year over year growth rate of 16.3%. The company is scheduled to announce its next quarterly earnings results after the market closes on Thursday, July 25th.
According to Zacks, analysts expect that Merit Medical Systems will report full year earnings of $2.02 per share for the current year, with EPS estimates ranging from $1.97 to $2.04. For the next fiscal year, analysts forecast that the company will post earnings of $2.36 per share, with EPS estimates ranging from $2.30 to $2.41. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Merit Medical Systems.
Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Tuesday, April 23rd. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.01. Merit Medical Systems had a return on equity of 10.99% and a net margin of 4.68%. The firm had revenue of $238.35 million for the quarter, compared to analyst estimates of $236.53 million. During the same period in the previous year, the firm earned $0.31 earnings per share. The company’s revenue was up 17.4% compared to the same quarter last year.
Several equities analysts have issued reports on MMSI shares. ValuEngine lowered Ultrapar Participacoes from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 25th. Zacks Investment Research lowered First Merchants from a “hold” rating to a “sell” rating in a research note on Monday, July 1st. Needham & Company LLC lowered Xilinx from a “buy” rating to a “hold” rating in a research note on Thursday, April 25th. Finally, BidaskClub raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $69.00.
MMSI traded down $0.76 during trading on Tuesday, hitting $55.02. The company’s stock had a trading volume of 681,715 shares, compared to its average volume of 328,079. Merit Medical Systems has a twelve month low of $49.40 and a twelve month high of $66.34. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.36 and a quick ratio of 1.25. The business’s fifty day simple moving average is $57.24. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of 32.56, a P/E/G ratio of 2.35 and a beta of 1.10.
In other Merit Medical Systems news, Director Nolan E. Karras sold 4,000 shares of the company’s stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $60.91, for a total value of $243,640.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at approximately $487,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Raul Jr. Parra sold 2,000 shares of the company’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $57.11, for a total value of $114,220.00. Following the completion of the transaction, the chief financial officer now owns 2,000 shares of the company’s stock, valued at approximately $114,220. The disclosure for this sale can be found here. Insiders sold a total of 14,000 shares of company stock valued at $844,820 in the last 90 days. Corporate insiders own 4.75% of the company’s stock.
Large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its position in shares of Merit Medical Systems by 5.9% in the fourth quarter. Bank of New York Mellon Corp now owns 875,501 shares of the medical instruments supplier’s stock worth $48,862,000 after acquiring an additional 48,526 shares in the last quarter. Advisor Group Inc. increased its position in shares of Merit Medical Systems by 287.2% in the fourth quarter. Advisor Group Inc. now owns 12,362 shares of the medical instruments supplier’s stock worth $691,000 after acquiring an additional 9,169 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Merit Medical Systems in the fourth quarter worth approximately $243,000. Great West Life Assurance Co. Can increased its position in shares of Merit Medical Systems by 7.5% in the fourth quarter. Great West Life Assurance Co. Can now owns 72,549 shares of the medical instruments supplier’s stock worth $3,735,000 after acquiring an additional 5,038 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Merit Medical Systems in the fourth quarter worth approximately $924,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.
Merit Medical Systems Company Profile
Merit Medical Systems, Inc manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions.
Featured Story: Gap Down Stocks
Get a free copy of the Zacks research report on Merit Medical Systems (MMSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.